Stanford



# Michaela Liedtke

CKD Family Professor

Medicine - Hematology


### CLINICAL OFFICE (PRIMARY)

- **Stanford Comprehensive Cancer Center**

  875 Blake Wilbur Dr Rm 2327

  MC 6560

  Stanford, CA 94305

  **Tel** (650) 498-6000 **Fax** (650) 724-5203


## Bio

### CLINICAL FOCUS

- Cancer > Hematology
- Cancer > Hematology > Leukemia - Acute and Chronic
- Multiple Myeloma
- Amyloidosis
- Hematology

### ACADEMIC APPOINTMENTS

- Professor-Univ Med Line, Medicine - Hematology
- Member, Cardiovascular Institute

### ADMINISTRATIVE APPOINTMENTS

- Co-Director, Stanford Amyloid Center, (2010- present)
- Member Leukemia Committee, Southwest Oncology Group, (2011- present)
- Medical Director, Stanford Adolescent and Young Adult Program, (2015- present)
- Unit Based Medical Director Inpatient Hematology, Stanford, (2019-2021)
- Cancer Center Program Lead, Hematology, Stanford, (2019- present)

### HONORS AND AWARDS

- Translational Research Award, Doris Duke Foundation (2004)
- Fellowship Award, Lymphoma Research Foundation (2004)
- Methods in Clinical Cancer Research Scholar, ASCO/AACR (2005)
- Research grant, Hope Street Kids Foundation (2006)
- Young Investigator Award, ASCO (2008)

- Translational Research Award, Stanford Department of Medicine (2011)

### BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Hematology (2002 - present)
- Member, American Society of Clinical Oncology (2002 - present)
- Member, International Myeloma Society (2012 - present)
- Member, Association of Northern California Oncologists (2014 - present)
- Member, International Society of Amyloidosis (2016 - present)

### PROFESSIONAL EDUCATION

- Medical Education: Medizinische Hochschule Hannover (1996) Germany
- Residency: Albert Einstein College of Medicine (2002) NY
- Fellowship: Memorial Sloan-Kettering Cancer Center (2004) NY
- Fellowship: Stanford University Medical Center (2005) CA
- Board Certification: Hematology, American Board of Internal Medicine (2005)

### LINKS

- Stanford Amyloid Center: http://stanfordhospital.org/clinicsmedServices/COE/heart/DiseasesConditions/amyloid/

## Research & Scholarship

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

1) Design of phase I/II trials for the treatment of Multiple Myeloma and Amyloidosis

2) Conduct of clinical trials to improve the treatment of patients with acute lymphoblastic leukemia (ALL)

3) Outcomes research using clinical databases for patients with Multiple Myeloma and Amyloidosis

### CLINICAL TRIALS

- Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1), Recruiting
- A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis, Not Recruiting
- A Safety Study of SEA-BCMA in Patients With Multiple Myeloma, Not Recruiting
- A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma, Not Recruiting
- A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia, Not Recruiting
- A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets, Not Recruiting
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES), Not Recruiting
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES), Not Recruiting
- A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis, Not Recruiting
- A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis, Not Recruiting
- Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Not Recruiting
- Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone, Not Recruiting

- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia, Not Recruiting
- Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab, Not Recruiting
- Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM), Not Recruiting
- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma, Not Recruiting
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia, Not Recruiting
- Longterm Follow-up of Subjects Treated With bb2121, Not Recruiting
- Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis, Not Recruiting
- Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma, Not Recruiting
- Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation, Not Recruiting
- Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis, Not Recruiting
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM, Not Recruiting
- Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia, Not Recruiting
- Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML, Not Recruiting
- Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65, Not Recruiting
- S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia, Not Recruiting
- S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia, Not Recruiting
- Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL), Not Recruiting
- Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL), Not Recruiting
- Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia, Not Recruiting
- Study of bb2121 in Multiple Myeloma, Not Recruiting
- Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies, Not Recruiting
- Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL, Not Recruiting
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma, Not Recruiting
- Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma, Not Recruiting
- Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma, Not Recruiting
- Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy, Not Recruiting
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma, Not Recruiting
- Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma, Not Recruiting
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis, Not Recruiting
- The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis, Not Recruiting
- A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement, Not Specified

- Connect® MM- The Multiple Myeloma Disease Registry, Not Specified

## Teaching

### GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

## Publications

### PUBLICATIONS

- **Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study.** *Blood*
  Zhong, X., Roberts, K. G., Wei, H., Sun, Z., Montefiori, L. E., Kumar, A., Iacobucci, I., Baviskar, P., Gao, Q., Pölönen, P., Pruett-Miller, S. M., Schreiber, R. M., Chang, et al
  2026

- **Cladribine and low-dose cytarabine as first salvage after hypomethylating agent and venetoclax in acute myeloid leukemia.** *Leukemia research*
  Dutta, R., Schumann, C., Cheung, E., Zhang, T. Y., Ediriwickrema, A., Fakhri, B., Gotlib, J., Liedtke, M., Shomali, W., Mannis, G. N.
  2026; 171: 108322

- **A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial.** *Nature medicine*
  Xu, J., Mei, C., Guan, X., Du, R., Wu, B., Wu, D., Li, M., Li, J., Song, Y., Su, H., Chen, X., Guo, Q., Chen, et al
  2026

- **Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.** *European journal of cancer (Oxford, England : 1990)*
  Valent, J., Zonder, J., Swenson, E. S., Catini, J., Manwani, R., Ahuja, B., Khan, Z., Liedtke, M.
  2026; 248: 117039

- **Pilot Study of Daratumumab for Reduction of Circulating Antibodies in Patients With High Allosensitization Awaiting Heart Transplantation.** *Journal of cardiac failure*
  Witteles, R. M., Zhang, B. M., Cheng, P., Liedtke, M., Teuteberg, J., Kobayashi, S., Chu, A., Alexander, K. M.
  2026; 32 (9): 1660-1664

- **Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Wechalekar, A. D., Dispenzieri, A., Sanchorawala, V., Kastritis, E., Bhutani, D., Bianchi, G., Jimenez-Zepeda, V. H., Suzuki, K., Lentzsch, S., Huart, A., Carpinteiro, A., Swenson, E. S., Khan, et al
  2026: JCO2600755

- **Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).** *Blood advances*
  Silva, W. F., Yin, J., Liedtke, M., Claxton, D., Fulton, N., Giri, S., Malnassy, G., Mrózek, K., Paietta, E., Mullighan, C. G., Galinsky, I. A., Bogart, J., Grecula, et al
  2026

- **First 30-patient safety and efficacy data from NEXICART-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, NXC-201**
  Landau, H., Raza, S., Rosenberg, A., Comenzo, R., Godara, A., Zonder, J., Sanchorawala, V., Kaufman, J., Abdallah, A., Liedtke, M., Yohannan, B., Anderson, L., Rosenzweig, et al
  CELL PRESS.2026: 3607-3610

- **Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.** *Blood cancer journal*
  Rana, M. S., Fernandez-Pol, S., Jensen, A., Hovanky, V., Velayati, A., Oak, J. S., Silva, O., Ames, E., Muffly, L. S., Sahaf, B., Arai, S., Kennedy, V. E., Bharadwaj, et al
  2026

- **Hepatic response criteria in light chain amyloidosis: a multicenter validation study.** *Haematologica*
  Muchtar, E., Palladini, G., Schonland, S., Geyer, S., Dooley, K. E., Dispenzieri, A., Wisniowski, B., Merlini, G., Milani, P., Hegenbart, U., Dittrich, T., Kastritis, E., Dimopoulos, et al

2026

- **Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE** *CLINICAL MEDICINE INSIGHTS-CARDIOLOGY*
  Nativi-Nicolau, J., Fajardo, J., Galloway, A., Khella, S., Kumar, N., Liedtke, M., Lousada, I., Patrick, T., Moffitt, C., Klein, L., Tamariz, G., Veeraraghavalu, K., Haddad-Angulo, et al
  2026; 20

- **Multiple Myeloma, Version 5.2026** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Costello, C., D'angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Godara, et al
  2026; 24 (1)

- **Derivation and External Validation of a Venous Thromboembolism Risk Prediction Model in Asparaginase-Treated ALL.** *Blood advances*
  Anderson, D. R., Gangaraju, R., Sedhom, W. G., Hamulyák, E. N., Wang, T. F., O'Dwyer, K. M., Carney, B. J., Muthiah, C., Liedtke, M., Badar, T., Shimony, S., Robinson, R., Sanfilippo, et al
  2025

- **Real-world performance of the CALGB 10403 regimen in young adults in the United States.** *Blood neoplasia*
  DaSilva, B., Darwin, A., Zhang, A., Vyas, R. D., Russell, K., Gilbert, J. S., Tan, V., Feldt, S., Johnston, H., Liang, E. C., DuVall, A. S., Liedtke, M., Stock, et al
  2025; 2 (3): 100111

- **Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.** *EJHaem*
  Paul, B., Minarik, J., Cottini, F., Gasparetto, C., Khouri, J., Gandhi, M., Hillengass, J., Levy, M., Liedtke, M., Manda, S., Sandhu, I., Sborov, D., Spicka, et al
  2025; 6 (3): e70072

- **NCCN Guidelines Insights: Multiple Myeloma, Version 1.2025.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Godara, et al
  2025; 23 (5): 132-140

- **Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.** *Nature communications*
  Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., Maltos, A. M., Silva, O., Stehr, H., Hovanky, V., Duran, G., Zhang, T., Liedtke, et al
  2025; 16 (1): 1824

- **Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma.** *Leukemia*
  Ravi, G., Richard, S., Kumar, S., Atrash, S., Liedtke, M., Kaur, G., Derman, B., Bergsagel, P. L., Mailankody, S., McCarthy, P., Shrestha, A., Kelly, L. M., Ly, et al
  2025

- **MGCS: where do we stand today?** *Hematology. American Society of Hematology. Education Program*
  Iberri, D., Liedtke, M.
  2024; 2024 (1): 482-488

- **Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Shah, B., Mattison, R. J., Abboud, R., Abdelmessieh, P., Aldoss, I., Burke, P. W., DeAngelo, D. J., Dinner, S., Fathi, A. T., Gauthier, J., Haddadin, M., Jain, N., Jonas, et al
  2024; 22 (8): 563-576

- **Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.** *JAMA oncology*
  Muchtar, E., Wisniowski, B., Geyer, S., Palladini, G., Milani, P., Merlini, G., Schönland, S., Veelken, K., Hegenbart, U., Leung, N., Dispenzieri, A., Kumar, S. K., Kastritis, et al
  2024

- **Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.** *The New England journal of medicine*

Litzow, M. R., Sun, Z., Mattison, R. J., Paietta, E. M., Roberts, K. G., Zhang, Y., Racevskis, J., Lazarus, H. M., Rowe, J. M., Arber, D. A., Wieduwilt, M. J., Liedtke, M., Bergeron, et al

2024; 391 (4): 320-333

- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*

  Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al

  2024

- **The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis.** *Leukemia & lymphoma*

  Palladini, G., Liedtke, M., Zago, W., Dolan, P., Kinney, G. G., Gertz, M. A.

  2024: 1-11

- **Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL.** *Blood advances*

  Zhao, Y., Laird, A. D., Roberts, K. G., Yafawi, R. L., Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S. M., Jabbour, E. J., Cassaday, et al

  2024

- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*

  Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al

  2024

- **Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*

  Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Derman, B., Devarakonda, S., Elsedawy, et al

  2024; 22 (1D): e240001

- **Implementation of a Pilot Clinic for Pediatric to Adult Cancer Survivorship Transitions.** *Journal of adolescent and young adult oncology*

  Jin, A. H., Simon, P. J., Clayton, A., Benedict, C., Liedtke, M., Muffly, L., Schapira, L., Smith, S. M.

  2023

- **Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.** *Nature medicine*

  Lin, Y., Raje, N. S., Berdeja, J. G., Siegel, D. S., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Massaro, M., Petrocca, F., Yeri, A., Finney, et al

  2023

- **Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.** *Blood*

  Gertz, M. A., Cohen, A. D., Comenzo, R. L., Kastritis, E., Landau, H. J., Libby, E. N., Liedtke, M., Sanchorawala, V., Schonland, S., Wechalekar, A. D., Zonder, J. A., Palladini, G., Walling, et al

  2023

- **Enrolling patients in Cardiac Amyloid Reaching for Extended Survival (CARES) trials: Two placebo-controlled, double-blind, randomized, international phase 3 trials assessing CAEL-101 in patients with Mayo stage IIIa or stage IIIb AL amyloidosis.**

  Liedtke, M., Palladini, G., Molina, M., Kastritis, E., Ianus, J., Catini, J., Quarta, C., Wechalekar, A. D., 301 & 302 Investigators

  LIPPINCOTT WILLIAMS & WILKINS.2023

- **Plasma cell leukemia: A multicenter retrospective study of 150 patients.**

  Chineke, I., Wertheim, B. C., Roe, D., Larsen, A., Sborov, D. W., Vardell, V., Green, D., Degraff, D., Liedtke, M., Okoniewski, M., Wazir, M., Nadeem, O., Shubert, et al

  LIPPINCOTT WILLIAMS & WILKINS.2023

- **A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.** *Future oncology (London, England)*

  Paul, B., Liedtke, M., Khouri, J., Rifkin, R., Gandhi, M. D., Kin, A., Levy, M. Y., Silbermann, R., Cottini, F., Sborov, D. W., Sandhu, I., Villarreal, L., Murphy, et al

  2023

- **Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.** *Nature medicine*

Mailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., Htut, M., Karski, E. E., Lovelace, et al

2023

- **Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*

  Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Devarakonda, S., Elsedawy, N., Garfall, et al

  2023; 21 (12): 1281-1301

- **Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*

  Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Campagnaro, E., Castillo, J. J., Costello, C., D'Angelo, C., Devarakonda, S., Elsedawy, N., Garfall, A., Godby, et al

  2023; 21 (1): 67-81

- **Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.** *Seminars in oncology*

  Testa, S., Kumar, J., Goodell, A. J., Zehnder, J. L., Alexander, K. M., Sidana, S., Arai, S., Witteles, R. M., Liedtke, M.

  2022

- **AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review.** *JACC. CardioOncology*

  Wechalekar, A. D., Fontana, M., Quarta, C. C., Liedtke, M.

  2022; 4 (4): 427-441

- **Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.** *Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis*

  Dispenzieri, A., Zonder, J., Hoffman, J., Wong, S. W., Liedtke, M., Abonour, R., D'Souza, A., Lee, C., Cote, S., Potluri, R., Ammann, E., Tran, N., Lam, et al

  2022: 1-8

- **The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study.** *Blood advances*

  Aldoss, I., Yin, J., Wall, A., Mrozek, K., Liedtke, M., Claxton, D., Foster, M. C., Appelbaum, F. R., Erba, H. P., Litzow, M. R., Tallman, M. S., Stone, R. M., Larson, et al

  2022

- **Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

  Muchtar, E., Dispenzieri, A., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., Schonland, S., Veelken, K., Hegenbart, U., Geyer, S. M., Kumar, S. K., Kastritis, E., Dimopoulos, et al

  2022: JCO2200643

- **Developing high-affinity decoy receptors to treat multiple myeloma and diffuse large B cell lymphoma.** *The Journal of experimental medicine*

  Miao, Y. R., Thakkar, K., Cenik, C., Jiang, D., Mizuno, K., Jia, C., Li, C. G., Zhao, H., Diep, A., Xu, Y., Zhang, X. E., Yang, T. T., Liedtke, et al

  2022; 219 (9)

- **Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.** *The New England journal of medicine*

  Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., Orlowski, R. Z., Anderson, L. D., Zonder, et al

  2022

- **Multiple Myeloma, Version 3.2022 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*

  Callander, N. S., Baljevic, M., Adekola, K., Anderson, L. D., Campagnaro, E., Castillo, J. J., Costello, C., Devarakonda, S., Elsedawy, N., Faiman, M., Garfall, A., Godby, K., Hillengass, et al

  2022; 20 (1): 9-19

- **Case Report: Mature Plasmacytoid Dendritic Cell Proliferation Associated With a Lymphoid Neoplasm.** *Frontiers in oncology*

  Fei, F., Liedtke, M., Silva, O.

  2022; 12: 903113

- **Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.** *Leukemia*
  Bal, S., Malek, E., Kansagra, A., Usmani, S. Z., Vij, R., Godby, K. N., Cornell, R. F., Kang, Y., Umyarova, E., Giri, S., Chhabra, S., Liedtke, M., Callander, et al
  2021

- **Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.** *Clinical lymphoma, myeloma & leukemia*
  Costa, L. J., Lin, Y., Cornell, R. F., Martin, T., Chhabra, S., Usmani, S. Z., Jagannath, S., Callander, N. S., Berdeja, J. G., Kang, Y., Vij, R., Godby, K. N., Malek, et al
  2021

- **A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma**
  Paul, B., Liedtke, M., Monge, J., Chaudhry, M., Rifkin, R., Gandhi, M., Khouri, J., Kin, A., Kovacsovics, T., Levy, M., Mohrbacher, A., Schmidt, W., Siegel, et al
  WILEY.2021: S11-S13

- **Triple-class refractory disease as a modern therapeutic benchmark for clinical trials testing new agents for relapsed refractory Multiple Myeloma**
  Malek, E., Kansagra, A., Costa, L., Usmani, S. Z., Vij, R., Kumar, S., Godby, K., Bal, S., Cornell, R., Kang, Y., Umyarova, E., Giri, S., Chhabra, et al
  CIG MEDIA GROUP, LP.2021: S148-S149

- **Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL.** *Blood advances*
  Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Kolitz, J. E., Liedtke, M., Stock, W., Beumer, J. H., Mattison, R. J., Storrick, E., Christner, S. M., Lewis, et al
  2021

- **A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.** *Blood cancer journal*
  Ramasamy, K., Nooka, A., Quach, H., Htut, M., Popat, R., Liedtke, M., Tuchman, S. A., Laubach, J., Gasparetto, C., Chanan-Khan, A., Hertzberg, M., deMario, M., Nueesch, et al
  2021; 11 (9): 149

- **Structural changes of corneal epithelium in belantamab-associated superficial keratopathy using anterior segment optical coherence tomography.** *American journal of ophthalmology case reports*
  Matsumiya, W., Karaca, I., Ghoraba, H., Akhavanrezayat, A., Mobasserian, A., Hassan, M., Regenold, J., Yasar, C., Liedtke, M., Kitazawa, K., Nguyen, Q. D.
  2021; 23: 101133

- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
  Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
  2021; 5 (16): 3147-3151

- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
  Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
  2021

- **Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.**
  Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., Liedtke, M.
  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data.** *Bone marrow transplantation*
  Badar, T., Szabo, A., Litzow, M., Burkart, M., Yurkiewicz, I., Dinner, S., Hefazi, M., Shallis, R. M., Podoltsev, N., Patel, A. A., Curran, E., Wadleigh, M., Balasubramanian, et al
  2021

- **Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis.** *Circulation. Heart failure*
  Witteles, R. M., Liedtke, M.
  2021: CIRCHEARTFAILURE120008225

- **Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.** *Blood advances*
  Advani, A. S., Larsen, E., Laumann, K., Luger, S. M., Liedtke, M., Devidas, M., Chen, Z., Yin, J., Foster, M. C., Claxton, D., Coffan, K., Tallman, M. S., Appelbaum, et al
  2021; 5 (2): 504–12

- **Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.** *Blood cancer journal*
  Premkumar, V. J., Lentzsch, S., Pan, S., Bhutani, D., Richter, J., Jagannath, S., Liedtke, M., Jaccard, A., Wechalekar, A. D., Comenzo, R., Sanchorawala, V., Royer, B., Rosenzweig, et al
  2021; 11 (1): 10

- **Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.** *Leukemia & lymphoma*
  Ladha, A. n., Hui, G. n., Cheung, E. n., Berube, C. n., Coutre, S. E., Gotlib, J. n., Liedtke, M. n., Zhang, T. Y., Muffly, L. n., Mannis, G. N.
  2021: 1–6

- **Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Brown, P. A., Shah, B., Advani, A., Aoun, P., Boyer, M. W., Burke, P. W., DeAngelo, D. J., Dinner, S., Fathi, A. T., Gauthier, J., Jain, N., Kirby, S., Liedtke, et al
  2021; 19 (9): 1079-1109

- **Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.** *Cancer*
  Stock, W., Martinelli, G., Stelljes, M., DeAngelo, D. J., Gokbuget, N., Advani, A. S., O'Brien, S., Liedtke, M., Merchant, A. A., Cassaday, R. D., Wang, T., Zhang, H., Vandendries, et al
  2020

- **Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.** *Blood cancer journal*
  DeAngelo, D. J., Advani, A. S., Marks, D. I., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., Jabbour, E., Merchant, A., Wang, T., Vandendries, E., Neuhof, A., Kantarjian, et al
  2020; 10 (8): 81

- **Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.** *Blood advances*
  Badar, T., Szabo, A., Advani, A., Wadleigh, M., Arslan, S., Khan, M. A., Aldoss, I., Siebenaller, C., Schultz, E., Hefazi, M., Shallis, R. M., Yurkiewicz, I., Podoltsev, et al
  2020; 4 (10): 2308–16

- **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**
  Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al
  LIPPINCOTT WILLIAMS & WILKINS.2020

- **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
  Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
  LIPPINCOTT WILLIAMS & WILKINS.2020

- **Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.** *Clinical lymphoma, myeloma & leukemia*
  Badar, T., Szabo, A., Wadleigh, M., Liedtke, M., Arslan, S., Siebenaller, C., Aldoss, I., Schultz, E., Hefazi, M., Litzow, M. R., Kuo, E., Wang, A., Curran, et al
  2020

- **Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience**
  Badar, T., Advani, A. S., Liedtke, M., Arslan, S., Khan, M., Aldoss, I., Sienbenaller, C., Schultz, E., Hefazi, M., Shallis, R., Yurkiewicz, I., Podoltsev, N., Patel, et al
  ELSEVIER SCIENCE INC.2020: S101–S102

- **Organ responses with daratumumab therapy in previously treated AL amyloidosis.** *Blood advances*
  Chung, A. n., Kaufman, G. P., Sidana, S. n., Eckhert, E. n., Schrier, S. L., Lafayette, R. A., Arai, S. n., Witteles, R. M., Liedtke, M. n.

2020; 4 (3): 458–66

- **Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.** *JACC. Heart failure*
  Barrett, C. D., Alexander, K. M., Zhao, H. n., Haddad, F. n., Cheng, P. n., Liao, R. n., Wheeler, M. T., Liedtke, M. n., Schrier, S. n., Arai, S. n., Weisshaar, D. n., Witteles, R. M.
  2020

- **Single-cell mutational profiling enhances the clinical evaluation of AML MRD.** *Blood advances*
  Ediriwickrema, A. n., Aleshin, A. n., Reiter, J. G., Corces, M. R., Köhnke, T. n., Stafford, M. n., Liedtke, M. n., Medeiros, B. C., Majeti, R. n.
  2020; 4 (5): 943–52

- **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*
  Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
  2020

- **Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
  Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., Faiman, M., Garfall, A., Godby, et al
  2020; 18 (12): 1685–1717

- **Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.** *Cancer*
  Badar, T. n., Szabo, A. n., Dinner, S. n., Liedtke, M. n., Burkart, M. n., Shallis, R. M., Yurkiewicz, I. R., Kuo, E. n., Khan, M. A., Balasubramanian, S. n., Yang, J. n., Hefazi, M. n., Podoltsev, et al
  2020

- **Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone versus standard of care in MAMMOTH.** *American journal of hematology*
  Cornell, R. n., Hari, P. n., Tang, S. n., Biran, N. n., Callander, N. n., Chari, A. n., Chhabra, S. n., Fiala, M. A., Gahvari, Z. n., Gandhi, U. n., Godby, K. n., Gupta, R. n., Jagannath, et al
  2020

- **Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia.** *Nature biotechnology*
  Granja, J. M., Klemm, S., McGinnis, L. M., Kathiria, A. S., Mezger, A., Corces, M. R., Parks, B., Gars, E., Liedtke, M., Zheng, G. X., Chang, H. Y., Majeti, R., Greenleaf, et al
  2019

- **Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.** *Leukemia research*
  Jabbour, E., Gokbuget, N., Advani, A., Stelljes, M., Stock, W., Liedtke, M., Martinelli, G., O'Brien, S., Wang, T., Laird, A. D., Vandendries, E., Neuhof, A., Nguyen, et al
  2019; 88: 106283

- **Multiple Myeloma, Version 1.2020 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Kumar, S. K., Callender, N. S., Hillengass, J., Liedtke, M., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Cornell, R. F., Costello, C., Efebera, Y., Faiman, M., Garfall, et al
  2019; 17 (10): 1155–65

- **Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)**
  Cornell, R., Parameswaran, H., Tang, S., Barnstead, A., Biran, N., Callander, N., Chari, A., Chhabra, S., Fiala, M., Gahvari, Z., Gandhi, U., Godby, K., Gupta, et al
  CIG MEDIA GROUP, LP.2019: E115–E116

- **Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy** *LEUKEMIA*
  Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., Malek, E., Mansour, J., Paul, et al
  2019; 33 (9): 2266–75

- **AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management** *JACC: CARDIOONCOLOGY*
  Witteles, R. M., Liedtke, M.
  2019; 1 (1): 117–30

- **Gene Signatures to Distinguish Amyloid Cardiomyopathy Risk in Multiple Myeloma Patients**
  Jha, A., Morgado, I., Lee, D. J., Alexander, K., Tsai, C., Schimmel, K., Ward, J., Witteles, R., Liedtke, M., Liao, R., Dangwal, S.
  LIPPINCOTT WILLIAMS & WILKINS.2019

- **Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study** *CANCER*
  Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Goekbuget, N., O'Brien, S. M., Jabbour, E., Wang, T., White, J., Sleight, B., Vandendries, E., Advani, et al
  2019; 125 (14): 2474–87

- **Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection**
  Aleshin, A., Durruthy-Durruthy, R., Corces, R., Liedtke, M., Eastburn, D., Majeti, R.
  AMER ASSOC CANCER RESEARCH.2019

- **Outcome of relapsed or refractory acute lymphoblastic leukemia patients with extramedullary disease or lymphoblastic lymphoma receiving inotuzumab ozogamicin or standard care in the INO-VATE trial**
  Marks, D. I., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S., Jabbour, E., Merchant, A., Wang, T., Vandendries, E., Neuhof, A., Advani, et al
  NATURE PUBLISHING GROUP.2019: 149–51

- **Grading cardiac response in AL amyloidosis: implications for relapse and survival** *BRITISH JOURNAL OF HAEMATOLOGY*
  Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
  2019; 186 (1): 144–46

- **B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma** *IMMUNOTHERAPY*
  Eckhert, E., Hewitt, R., Liedtke, M.
  2019; 11 (9): 801–11

- **Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma** *NEW ENGLAND JOURNAL OF MEDICINE*
  Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., Lam, L., Morgan, R. A., Friedman, et al
  2019; 380 (18): 1726–37

- **A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403** *BLOOD*
  Stock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., Paietta, E., Parker, E., Geyer, et al
  2019; 133 (14): 1548–59

- **Contemporary Outcomes in Patients with Cardiac Amyloidosis Undergoing Heart Transplantation**
  Alexander, K., Barrett, C., Dobos, K., Cheng, P., Liao, R., Wheeler, M., Liedtke, M., Weisshaar, D., Witteles, R.
  ELSEVIER SCIENCE INC.2019: S215

- **Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.** *Cancer*
  Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gokbuget, N., O'Brien, S. M., Jabbour, E., Wang, T., Liang White, J., Sleight, B., Vandendries, E., Advani, et al
  2019

- **Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.** *Leukemia*
  Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., Malek, E., Mansour, J., Paul, et al
  2019

- **Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.** *Best practice & research. Clinical haematology*
  Chung, A., Liedtke, M.
  2019; 32 (1): 54–64

- **Therapy-related myeloid neoplasms after treatment for plasma-cell disorders** *BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY*
  Chung, A., Liedtke, M.
  2019; 32 (1): 54–64

- **Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.** *American journal of hematology*
  Jabbour, E., Advani, A. S., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., Martinelli, G., O'Brien, S., White, J. L., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, et al
  2019

- **Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.** *Blood advances*
  Saygin, C. n., Kishtagari, A. n., Cassaday, R. D., Reizine, N. n., Yurkiewicz, I. n., Liedtke, M. n., Stock, W. n., Larson, R. A., Levine, R. L., Tallman, M. S., Park, J. H., Kerr, C. n., Przychodzen, et al
  2019; 3 (24): 4228–37

- **Cutaneous plasmablastic plasmacytoma.** *Blood*
  Chung, A. n., Liedtke, M. n.
  2019; 134 (23): 2116

- **A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.** *JACC. Heart failure*
  Barrett, C. D., Dobos, K. n., Liedtke, M. n., Tuzovic, M. n., Haddad, F. n., Kobayashi, Y. n., Lafayette, R. n., Fowler, M. B., Arai, S. n., Schrier, S. n., Witteles, R. M.
  2019

- **Grading cardiac response in AL amyloidosis: implications for relapse and survival.** *British journal of haematology*
  Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
  2018

- **Daratumumab vs. pomalidomide for the treatment of relapsed/refractory multiple myeloma: a cost-effectiveness analysis.** *American journal of hematology*
  Gong, C. L., Studdert, A. L., Liedtke, M.
  2018

- **Antibody-based therapies in patients with acute lymphoblastic leukemia.** *Hematology. American Society of Hematology. Education Program*
  Dinner, S., Liedtke, M.
  2018; 2018 (1): 9–15

- **A Phase II Study of Dasatinib and Dexamethasone As Primary Therapy Followed By Transplantation for Adults with Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia (Ph plus ALL): Final Results of Alliance/CALGB Study 10701**
  Wieduwilt, M. J., Yin, J., Wetzler, M., Uy, G. L., Powell, B. L., Kolitz, J. E., Liedtke, M., Stock, W., Beumer, J. H., Mattison, R. J., Storrick, E., Devine, S., Smith, et al
  AMER SOC HEMATOLOGY.2018

- **Single-Cell Mutational Profiling of Clonal Evolution in De Novo AML during Therapy and Relapse**
  Aleshin, A., Durruthy-Durruthy, R., Corces, M., Stafford, M., Liedtke, M., Medeiros, B. C., Eastburn, D. J., Majeti, R.
  AMER SOC HEMATOLOGY.2018

- **Antibody-based therapies in patients with acute lymphoblastic leukemia** *HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM*
  Dinner, S., Liedtke, M.
  2018: 9-15

- **Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma** *BRITISH JOURNAL OF HAEMATOLOGY*
  Richardson, P. G., Hofmeister, C. C., Rosenbaum, C. A., Htut, M., Vesole, D. H., Berdeja, J. G., Liedtke, M., Chari, A., Smith, S. D., Lebovic, D., Raje, N., Byrne, C., Liao, et al
  2018; 182 (2): 231–44

- **Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients.** *Journal of adolescent and young adult oncology*
  Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., Dunn, T.

2018

- **Effect of Fitbit and iPad Wearable Technology in Health-Related Quality of Life in Adolescent and Young Adult Cancer Patients** *JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY*
  Yurkiewicz, I. R., Simon, P., Liedtke, M., Dahl, G., Dunn, T.
  2018; 7 (5): 579–83

- **Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE** *CANCER*
  Jabbour, E. J., DeAngelo, D. J., Stelljes, M., Stock, W., Liedtke, M., Gokbuget, N., O'Brien, S., Wang, T., Paccagnella, M., Sleight, B., Vandendries, E., Advani, A. S., Kantarjian, et al
  2018; 124 (8): 1722–32

- **Clinical implications of gastrointestinal symptoms in systemic amyloidosis** *NEUROGASTROENTEROLOGY AND MOTILITY*
  Yen, T., Chen, F. W., Witteles, R. M., Liedtke, M., Nguyen, L. A.
  2018; 30 (4): e13229

- **Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).** *Leukemia research*
  Advani, A. S., Li, H. n., Michaelis, L. C., Medeiros, B. C., Liedtke, M. n., List, A. F., O'Dwyer, K. n., Othus, M. n., Erba, H. P., Appelbaum, F. R.
  2018; 67: 17–20

- **Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia** *DRUG DESIGN DEVELOPMENT AND THERAPY*
  Yurkiewicz, I. R., Muffly, L., Liedtke, M.
  2018; 12: 2293–2300

- **A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.** *International journal of hematology*
  Dinner, S. n., Dunn, T. J., Price, E. n., Coutré, S. E., Gotlib, J. n., Berube, C. n., Kaufman, G. P., Medeiros, B. C., Liedtke, M. n.
  2018

- **Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response** *LEUKEMIA & LYMPHOMA*
  Saygin, C., Papadantonakis, N., Cassaday, R. D., Liedtke, M., Fischer, K., Dunn, T., Patel, B. J., Sobecks, R., Kalaycio, M., Sekeres, M. A., Mukherjee, S., Gerds, A. T., Hamilton, et al
  2018; 59 (2): 363–71

- **NCCN Guidelines (R) Insights Multiple Myeloma, Version 3.2018 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J., Castillo, J., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Godby, K., Hofmeister, C., Holmberg, et al
  2018; 16 (1): 11–20

- **Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis**
  Yen, T., Chen, F., Witteles, R., Liedtke, M., Nguyen, L.
  NATURE PUBLISHING GROUP.2017: S240

- **Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow** *CANCER IMMUNOLOGY RESEARCH*
  Hansmann, L., Han, A., Penter, L., Liedtke, M., Davis, M. M.
  2017; 5 (9): 744–54

- **Novel therapeutic approaches for AL amyloid**
  Liedtke, M.
  KARGER.2017: 194

- **NEOD001 DEMONSTRATES DURABLE PERIPHERAL NEUROPATHY RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS AND PERSISTENT ORGAN DYSFUNCTION: RESULTS FROM A PHASE 1/2 STUDY**
  Gertz, M., Comenzo, R. L., Landau, H., Sanchorawala, Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G. G., Koller, M., Schenk, D. B., Guthrie, S. D., Liu, E., Alvarez-Baron, E., et al
  WILEY.2017: 289–90

- **NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous hematologic response**
  Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., Schoenland, S. O., Walling, J., Kinney, G. G., Koller, M., Schenk, D. B., Guthrie, S. D., Liu, et al
  KARGER.2017: 34–35

- **Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis** *BLOOD*
  Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., Liedtke, M.
  2017; 130 (7): 900–902

- **Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study** *BLOOD ADVANCES*
  DeAngelo, D. J., Stock, W., Stein, A. S., Shustov, A., Liedtke, M., Schiffer, C. A., Vandendries, E., Liau, K., Ananthakrishnan, R., Boni, J., Laird, A., Fostvedt, L., Kantarjian, et al
  2017; 1 (15): 1167–80

- **NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction independently of previous haematological response**
  Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G. G., Koller, M., Schenk, D. B., Guthrie, S. D., Liu, E., Gertz, et al
  WILEY.2017: 441

- **NEOD001 DEMONSTRATES CARDIAC BIOMARKER RESPONSES IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS: RESULTS FROM THE PHASE 1/2 STUDY**
  Liedtke, M., Comenzo, R., Landau, H., Sanchorawala, V., Weiss, B., Zonder, J., Walling, J., Kinney, G., Koller, M., Schenk, D. B., Guthrie, S., Liu, E., Gertz, et al
  ELSEVIER SCIENCE INC.2017: 825

- **Recommendations from the Amyloidosis Research Consortium Educational Roundtable at the American College of Cardiology Annual Meeting, 1 April 2016**
  Maurer, M., Lousada, I., Hanna, M., Ruberg, F., Mohty, D., Dispenzieri, A., Liedtke, M., Paulson, I., Vest, J., Grogan, M.
  TAYLOR & FRANCIS LTD.2017: 165–66

- **Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, et al
  2017; 15 (2): 230-?

- **Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.** *Leukemia*
  DeAngelo, D. J., George, T. I., Linder, A. n., Langford, C. n., Perkins, C. n., Ma, J. n., Westervelt, P. n., Merker, J. D., Berube, C. n., Coutre, S. n., Liedtke, M. n., Medeiros, B. n., Sternberg, et al
  2017

- **Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).** *The American journal of cardiology*
  Tuzovic, M. n., Kobayashi, Y. n., Wheeler, M. n., Barrett, C. n., Liedtke, M. n., Lafayette, R. n., Schrier, S. n., Haddad, F. n., Witteles, R. n.
  2017; 120 (8): 1381–86

- **Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.** *New England journal of medicine*
  Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O'Brien, S., Wang, K., Wang, T., Paccagnella, M. L., Sleight, B., Vandendries, et al
  2016; 375 (8): 740-753

- **NEOD001 demonstrates cardiac biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion phase of a phase 1/2 study**
  Liedtke, M., Comenzo, R. L., Landau, H., Sanchorawala, V., Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G. G., Koller, M., Gertz, M. A.
  OXFORD UNIV PRESS.2016: 220

- **A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.** *British journal of haematology*
  Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., Berube, C., Medeiros, B. C., Liedtke, M.

2016; 173 (2): 253-259

- **Multiple Myeloma, Version 3.2016 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Djulbegovic, B., Fung, H. C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, et al
  2016; 14 (4): 389-400

- **First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.** *Journal of clinical oncology*
  Gertz, M. A., Landau, H., Comenzo, R. L., Seldin, D., Weiss, B., Zonder, J., Merlini, G., Schönland, S., Walling, J., Kinney, G. G., Koller, M., Schenk, D. B., Guthrie, et al
  2016; 34 (10): 1097-1103

- **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.** *Leukemia & lymphoma*
  Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
  2016; 57 (3): 609-615

- **Recurrent Subepidermal Blistering Dermatosis Heralding Disease Relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature.** *Clinical lymphoma, myeloma & leukemia*
  Leatham, H. W., Novoa, R., Liedtke, M., Kwong, B. Y.
  2016; 16 (1): e1-5

- **Identification of Doxorubicin as an Inhibitor of the IRE1a-XBP1 Axis of the Unfolded Protein Response.** *Scientific reports*
  Jiang, D., Lynch, C., Medeiros, B. C., Liedtke, M., Bam, R., Tam, A. B., Yang, Z., Alagappan, M., Abidi, P., Le, Q., Giaccia, A. J., Denko, N. C., Niwa, et al
  2016; 6: 33353-?

- **Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia**
  Advani, A. S., Li, H., Michaelis, L. C., Medeiros, B. C., Liedtke, M., List, A. F., O'Dwyer, K., Othus, M., Erba, H. P., Appelbaum, F. R.
  AMER SOC HEMATOLOGY.2015

- **Multiple Myeloma, Version 2.2016** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Anderson, K. C., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Djulbegovic, B., Fung, H. C., Gasparetto, C., Godby, K., Hofmeister, C., Holmberg, L., Holstein, et al
  2015; 13 (11): 1398-1435

- **CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.** *Cell stem cell*
  Iwasaki, M., Liedtke, M., Gentles, A. J., Cleary, M. L.
  2015; 17 (4): 412-421

- **Mass Cytometry Analysis Shows That a Novel Memory Phenotype B Cell Is Expanded in Multiple Myeloma** *CANCER IMMUNOLOGY RESEARCH*
  Hansmann, L., Blum, L., Ju, C., Liedtke, M., Robinson, W. H., Davis, M. M.
  2015; 3 (6): 650-660

- **The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.**
  Liedtke, M., Merlini, G., Landau, H., Comenzo, R., Seldin, D. C., Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G., Koller, M., Gertz, M. A.
  AMER SOC CLINICAL ONCOLOGY.2015

- **Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.** *American journal of transplantation*
  Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., Lafayette, R., Coakley, T., Witteles, R. M.
  2015; 15 (3): 650-658

- **A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis**
  Cohen, A. D., Scott, E. C., Liedtke, M., Kaufman, J. L., Landau, H., Vesole, D. H., Gomes, C. L., Gasparetto, C., Lentzsch, S., Rosenzweig, M., Sanchorawala, V., Smith, D. D., Comenzo, et al

AMER SOC HEMATOLOGY.2014

- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia** *LEUKEMIA RESEARCH*
  Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berubea, C., Gotlib, J., Patel, S., Medeiros, B.
  2014; 38 (12): 1441-1445

- **Indolent T-lymphoblastic Proliferation With Disseminated Multinodal Involvement and Partial CD33 Expression.** *American journal of surgical pathology*
  Ohgami, R. S., Sendamarai, A. K., Atwater, S. K., Liedtke, M., Fleming, M. D., Natkunam, Y., Warnke, R. A.
  2014; 38 (9): 1298-1304

- **Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia** *LEUKEMIA & LYMPHOMA*
  Dinner, S., Lee, D., Liedtke, M.
  2014; 55 (8): 1715-1724

- **Effects of serum and plasma matrices on multiplex immunoassays.** *Immunologic research*
  Rosenberg-Hasson, Y., Hansmann, L., Liedtke, M., Herschmann, I., Maecker, H. T.
  2014; 58 (2-3): 224-233

- **Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis** *HEART RHYTHM*
  Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., Schrier, S. L., Witteles, R. M.
  2014; 11 (1): 158-162

- **A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia.** *Leukemia & lymphoma*
  Patel, S., Liedtke, M., Ngo, D., Medeiros, B. C.
  2013; 54 (10): 2231-2235

- **Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.** *Haematologica*
  Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S. L., Liedtke, M.
  2013; 98 (10): 1593-1599

- **AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., Rappley, I., Vogel, H., Liedtke, M., Witteles, R. M., Powers, E. T., Reixach, N., Chan, et al
  2013; 110 (24): 9992-9997

- **The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis** *BRITISH JOURNAL OF HAEMATOLOGY*
  Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., George, T. I., Schrier, S. L., Liedtke, M.
  2013; 161 (3): 367-372

- **Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.** *Haematologica*
  Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., Greenberg, P., Zhang, B., Liedtke, M., Berube, C., Levine, R., Mitchell, B. S., Medeiros, et al
  2013; 98 (4): 591-596

- **Multiple Myeloma, Version 1.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
  Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Cohen, A. D., Devine, S., Djulbegovic, B., Faber, E. A., Gasparetto, C., Hernandez-Illizaliturri, F., Huff, C. A., Kassim, A., Krishnan, et al
  2013; 11 (1): 11-17

- **Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
  Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., Liedtke, M.
  AMER SOC HEMATOLOGY.2012

- **Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
  Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., Bates, J., Sekeres, M. A., Coutre, S., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al
  2012; 87 (10): 957-960

- **Hemophagocytic lymphohistiocytosis in pregnancy: A case report and review of treatment options.** *Hematology (Amsterdam, Netherlands)*
  Dunn, T., Cho, M., Medeiros, B., Logan, A., Ungewickell, A., Liedtke, M.
  2012

- **Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia** *LEUKEMIA*
  Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., Bhattacharya, S., Zehnder, J., Liedtke, M., Gotlib, J. R., Coutre, S., Berube, C., Melnick, et al
  2012; 26 (5): 893-901

- **More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis** *ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY*
  Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., Afghahi, A., Liedtke, M.
  2012; 138 (5): 509-511

- **Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*
  Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.
  2012; 31 (3): 325-331

- **The Transcription Factor Encyclopedia** *GENOME BIOLOGY*
  Yusuf, D., Butland, S. L., Swanson, M. I., Bolotin, E., Ticoll, A., Cheung, W. A., Zhang, X. Y., Dickman, C. T., Fulton, D. L., Lim, J. S., Schnabl, J. M., Ramos, O. H., Vasseur-Cognet, et al
  2012; 13 (3)

- **Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
  Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., Bhat, N. M., Teng, N. N., Coutre, S. E.
  2012; 97 (1): 30-37

- **Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy** *15th Annual Scientific Meeting of the Heart-Failure-Society-of-America*
  Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.
  CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2011: S45–S46

- **Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience** *AMERICAN JOURNAL OF HEMATOLOGY*
  Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Alizadeh, A. A., Medeiros, B. C.
  2010; 85 (11): 877-881

- **Plasma cell leukemia: concepts and management.** *Expert review of hematology*
  Liedtke, M., Medeiros, B. C.
  2010; 3 (5): 543-549

- **Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6** *BLOOD*
  Liedtke, M., Ayton, P. M., Somervaille, T. C., Smith, K. S., Cleary, M. L.
  2010; 116 (1): 63-70

- **Therapeutic targeting of MLL** *BLOOD*
  Liedtke, M., Cleary, M. L.
  2009; 113 (24): 6061-6068

- **Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma** *LEUKEMIA & LYMPHOMA*
  Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., Medeiros, B.
  2008; 49 (3): 581-585

- **Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population** *ANNALS OF ONCOLOGY*
  Liedtke, M., Hamlin, P. A., Moskowitz, C. H., Zelenetz, A. D.
  2006; 17 (6): 909-913

- **Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase** *ONCOGENE*
  Liedtke, M., Pandey, P., Kumar, S., KHARBANDA, S., Kufe, D.
  1998; 17 (15): 1889-1892

- **A SITE-DIRECTED MUTAGENESIS STUDY TO IDENTIFY AMINO-ACID-RESIDUES INVOLVED IN THE CATALYTIC FUNCTION OF THE RESTRICTION ENDONUCLEASE ECORV** *BIOCHEMISTRY*
  SELENT, U., RUTER, T., Kohler, E., Liedtke, M., THIELKING, V., Alves, J., Oelgeschlager, T., Wolfes, H., Peters, F., Pingoud, A.
  1992; 31 (20): 4808-4815